Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 12—December 2023
Dispatch

Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

Caitlin A. ContagComments to Author , Leah Mische, Isabel Fong, Abraar Karan, Akanksha Vaidya, David W. McCormick, William Bower, Jill K. Hacker, Kelly Johnson, Perla SanJuan, Linda Crebbin, Caroline Temmins, Harleen Sahni, Yael Bogler, Joseph D. Cooper, and Supriya Narasimhan
Author affiliations: Stanford University School of Medicine, Stanford, California, USA (C.A. Contag, L. Mische, A. Karan); Santa Clara Valley Medical Center, San Jose, California, USA (I. Fong, C. Temmins, H. Sahni, Y. Bogler, J.D. Cooper, S. Narasimhan); County of Santa Clara Public Health Department, Santa Clara, California, USA (A. Vaidya, P. SanJuan); Centers for Disease Control and Prevention. Atlanta, Georgia, USA (D.W. McCormick, W. Bower); California Department of Public Health. Richmond, California, USA (J.K. Hacker, K. Johnson, L. Crebbin); University of California, San Francisco, California, USA (K. Johnson, P. SanJuan)

Main Article

Table

Summary of antiviral therapy received by immunocompromised patient with mpox, California, USA, 2022

Antiviral therapy Dose Days administered*
Tecovirimat 200 mg orally twice daily 0–14, 56–125
Cidofovir 5 mg/kg intravenously weekly 89, 96
Brincidofovir 200 mg orally weekly 103, 111, 117, 124, 132, 140
Vaccinia immune globulin 576,000 units intravenously 92

*Day 0 was the date the patient first sought care at an urgent care clinic.

Main Article

Page created: October 19, 2023
Page updated: November 18, 2023
Page reviewed: November 18, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external